Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.

ABSTRACT: Accelerated-phase (AP) or blast-phase (BP) myeloproliferative neoplasms (MPNs) are associated with dismal prognosis, with non-curative therapies such as hypomethylating agents (HMAs) considered in patients not eligible for intensive therapy, while some studies advocate for combination therapy with either ruxolitinib (RUXO) or venetoclax (VEN). To assess the relationship between treatment modalities and outcome, herein, we report a multicentric cohort of 149 patients (median age, 75 years) with AP/BP MPN not eligible for intensive therapy and/or allogeneic hematopoietic cell transplantation who received azacitidine (AZA) alone (n = 60) or in combination (n = 89; VEN [n = 51], RUXO [n = 27], or both [n = 9], isocitrate dehydrogenase inhibitors [n = 2

SUBMITTER: Orvain C 

PROVIDER: S-EPMC12410146 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature